NCT01432275

Brief Summary

The aim of this study is to evaluate user preference and ease of use of the FreeStyle InsuLinx system, compared to current methodology, when used at home by subjects with diabetes. Subjects will also be comparing the ease of use of the FreeStyle InsuLinx system with comparator meters.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
179

participants targeted

Target at P50-P75 for not_applicable diabetes-mellitus

Timeline
Completed

Started Sep 2011

Shorter than P25 for not_applicable diabetes-mellitus

Geographic Reach
1 country

7 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2011

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

September 9, 2011

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 12, 2011

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2012

Completed
5.3 years until next milestone

Results Posted

Study results publicly available

August 4, 2017

Completed
Last Updated

August 4, 2017

Status Verified

April 1, 2017

Enrollment Period

7 months

First QC Date

September 9, 2011

Results QC Date

July 10, 2013

Last Update Submit

April 27, 2017

Conditions

Keywords

DiabetesSMBGInsulin calculator

Outcome Measures

Primary Outcomes (1)

  • Overall User Preference for the FreeStyle InsuLinx System Compared to Current Method.

    Overall user preference of the FreeStyle InsuLinx system as a diabetes management tool when compared against their usual method.

    25 days

Secondary Outcomes (1)

  • Preference Questionnaire (Insulin Calculator Not Activated)

    25 days (results recorded after the two 7 day periods)

Study Arms (2)

ADC, Then Comparator, Then ADC With Calculator

EXPERIMENTAL

Subject used the ADC blood glucose meter for 7 days with the insulin calculator not activated, followed by a comparator blood glucose meter for 7 days. For the last 10 days the subject used the ADC blood glucose meter with insulin calculator active.

Device: ADC blood glucose meterDevice: Comparator blood glucose meterDevice: ADC blood glucose meter with insulin calculator active

Comparator, Then ADC, Then ADC With Calculator

EXPERIMENTAL

Subject used a comparator blood glucose meter for 7 days, followed by the ADC blood glucose meter for 7 days, with the insulin calculator not activated. For the last 10 days the subject used the ADC blood glucose meter with insulin calculator active.

Device: ADC blood glucose meterDevice: Comparator blood glucose meterDevice: ADC blood glucose meter with insulin calculator active

Interventions

Subjects used the FreeStyle InsuLinx with the insulin calculator not activated. Subjects had not previously used the FreeStyle InsuLinx meter.

Also known as: Abbott Freestyle InsuLinx
ADC, Then Comparator, Then ADC With CalculatorComparator, Then ADC, Then ADC With Calculator

Subjects were randomly assigned one of the comparator meters. Subjects had not previously used the assigned comparator meter.

Also known as: Roche Accu-Chek Aviva Nano, Lifescan Verio Pro or, Bayer Contour USB
ADC, Then Comparator, Then ADC With CalculatorComparator, Then ADC, Then ADC With Calculator

Subjects used the FreeStyle InsuLinx with the insulin calculator activated.

Also known as: Abbott FreeStyle InsuLinx
ADC, Then Comparator, Then ADC With CalculatorComparator, Then ADC, Then ADC With Calculator

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject with Type 1 or 2 diabetes on a bolus regime (U100 insulin), one or more bolus injections per day for at least 6 months;
  • Age 18 yrs and above;
  • Regularly testing SMBG 3 or more times per day;
  • Willingness to test at least 4 times per day.

You may not qualify if:

  • Know to require a bolus injection of more than 50U in a single dose;
  • Has previously used either the InsuLinx or assigned comparison meter;
  • Participated in structured diabetes management training in the last 6 months
  • Is currently on an insulin pump;
  • Has concomitant disease that, in the Investigator's opinion, may compromise patient safety;
  • Is participating in another study of a glucose monitoring device or drug that could affect glucose measurements or glucose management;
  • Female subject who is pregnant or planning to become pregnant during the course of the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (7)

Tameside Hospital NHS Foundation Trust

Ashton-under-Lyne, OL6 9RW, United Kingdom

Location

Ayr Hospital

Ayr, KA6 6DX, United Kingdom

Location

Royal United Hospital

Bath, BA1 3NG, United Kingdom

Location

Royal Blackburn Hospital

Blackburn, BB2 7PL, United Kingdom

Location

North Manchester Diabetes Centre

Crumpsall, M8 5RB, United Kingdom

Location

Ipswich Hospital NHS Trust

Ipswich, IP4 5PD, United Kingdom

Location

Greenwood & Sneinton Family Medical Centre

Nottingham, NG3 7DQ, United Kingdom

Location

MeSH Terms

Conditions

Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Results Point of Contact

Title
Snr Director, Clinical Development & Regulatory Affairs
Organization
Abbott Diabetes Care

Study Officials

  • Shenaz Ramtoola

    Royal Blackburn Hospital

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
GT60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 9, 2011

First Posted

September 12, 2011

Study Start

September 1, 2011

Primary Completion

April 1, 2012

Study Completion

April 1, 2012

Last Updated

August 4, 2017

Results First Posted

August 4, 2017

Record last verified: 2017-04

Locations